Literature DB >> 32898651

Relationship between the cardiac magnetic resonance derived extracellular volume fraction and feature tracking myocardial strain in patients with non-ischemic dilated cardiomyopathy.

Mai Azuma1, Shingo Kato2, Sho Kodama1, Keigo Hayakawa1, Minako Kagimoto1, Kohei Iguchi1, Masahiro Fukuoka1, Kazuki Fukui1, Tae Iwasawa3, Daisuke Utsunomiya4, Kazuo Kimura5, Kouichi Tamura6.   

Abstract

BACKGROUND: Feature tracking (FT) has emerged as a promising method to quantify myocardial strain using conventional cine magnetic resonance imaging (MRI). Extracellular volume fraction (ECV) by T1 mapping enables quantification of myocardial fibrosis. To date, the correlation between FT-derived left ventricular strain and ECV has not been elucidated yet. The aim of this study was to evaluate the relationship between myocardial strain by FT and ECV by T1 mapping in patients with non-ischemic dilated cardiomyopathy (NIDCM).
METHODS: A total of 57 patients with NIDCM (61 ± 12 years; 46 (81%) male)) and 15 controls (62 ± 11 years; 11 (73%) male)) were studied. Using a 1.5 T magnetic resonance scanner, pre- and post- T1 mapping images of the LV wall at the mid-ventricular level were acquired to calculate the ECV by a modified Look-Locker inversion recovery (MOLLI) sequence. The radial strain (RS), circumferential strain (CS), and longitudinal strain (LS) were assessed by the FT technique. The ECV and myocardial strain were compared using a 6-segment model at the mid-ventricular level.
RESULTS: The ECV and myocardial strain were evaluable in all 432 segments in 72 subjects. On a patient-based analysis, NIDCM patients had a significantly higher ECV (0.30 ± 0.07 vs. 0.28 ± 0.06, p = .007) and impaired myocardial strain than the control subjects (RS, 22.7 ± 10.3 vs. 30.3 ± 18.2, p < .01; CS, -6.47 ± 1.89 vs. -9.52 ± 5.15, p < .001; LS -10.2 ± 3.78 vs. -19.8 ± 4.30, p < .001, respectively). A significant linear correlation was found between the RS and ECV (r = -0.38, p < .001) and CS and ECV, (r = 0.38, p < .001). LS and ECV also correlated (r = 0.31, p < 0.001). On a segment-based analysis, there was a significant correlation between the ECV and RS and ECV and CS (all p values < .05). The intraclass correlation coefficient was good for the strain measurement (>0.80).
CONCLUSIONS: In patients with NIDCM, significant correlation was found between myocardial strain and ECV, suggesting the FT-derived myocardial strain might be useful as a non-invasive imaging marker for the detection of myocardial fibrosis without any contrast media.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extracellular volume fraction; Feature tracking; Magnetic resonance; Non-ischemic dilated cardiomyopathy; T1 mapping

Mesh:

Year:  2020        PMID: 32898651     DOI: 10.1016/j.mri.2020.09.004

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  3 in total

1.  Myocardium Assessment by Relaxation along Fictitious Field, Extracellular Volume, Feature Tracking, and Myocardial Strain in Hypertensive Patients with Left Ventricular Hypertrophy.

Authors:  Seyed Amir Mirmojarabian; Eveliina Lammentausta; Esa Liukkonen; Lauri Ahvenjärvi; Juhani Junttila; Miika T Nieminen; Timo Liimatainen
Journal:  Int J Biomed Imaging       Date:  2022-06-23

2.  Different Impacts on the Heart After COVID-19 Infection and Vaccination: Insights From Cardiovascular Magnetic Resonance.

Authors:  Jan Gröschel; Yashraj Bhoyroo; Edyta Blaszczyk; Ralf Felix Trauzeddel; Darian Viezzer; Hadil Saad; Maximilian Fenski; Jeanette Schulz-Menger
Journal:  Front Cardiovasc Med       Date:  2022-07-14

3.  Cardiovascular magnetic resonance imaging patterns of acute COVID-19 mRNA vaccine-associated myocarditis in young male patients: A first single-center experience.

Authors:  Ruben Evertz; Alexander Schulz; Torben Lange; Sören J Backhaus; Dirk Vollmann; Johannes T Kowallick; Stephan von Haehling; Gerd Hasenfuß; Andreas Schuster
Journal:  Front Cardiovasc Med       Date:  2022-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.